Association analysis showed that positive Pten-NOLC1 fusion transcript detection in the blood sample is associated with better cancer differentiation (lower Gleason’s grading, p = 0.042), with 62.5% Gleason 6 is positive for Pten-NOLC1, while only 38.4% for Gleason 7-8 and 16.7% for Gleason 9-10 (Table 1). Here, PTEN is linked to cancer.